First-line combined Checkpoint Blockade in Patents with MSI-H/dMMR mCRC

被引：0
|
作者：
Klein, Friederike
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2022年 / 60卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2023, 20 : 138 - 138
  • [32] Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (02) : 79 - 79
  • [33] MSI-H/dMMR-CRC: Langzeitdaten bestätigen Immuntherapie
    Friederike Klein
    Gastro-News, 2021, 8 (6) : 61 - 63
  • [34] NIVOLUMAB HAS ANTITUMOR ACTIVITY IN DMMR/MSI-H COLORECTAL CANCER
    CANCER DISCOVERY, 2017, 7 (09) : 930 - 930
  • [35] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [36] Real-world (RW) treatment patterns and clinical outcomes for chemotherapy-based regimens in first line (1L) MSI-H/dMMR metastatic colorectal cancer (mCRC).
    Chase, Monica
    Amonkar, Mayur
    Myer, Nicole
    Wang, Tongtong
    Turzhitsky, Vladimir
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18755 - E18755
  • [37] Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors.
    Lenz, Heinz-Josef
    Nicolaides, Theodore
    Elliott, Andrew
    Goldberg, Richard M.
    Marshall, John
    Lou, Emil
    Shields, Anthony Frank
    Sohal, Davendra
    Weinberg, Benjamin Adam
    Spetzler, David
    Abraham, Jim
    Xiu, Joanne
    Korn, Wolfgang Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 202 - 202
  • [38] Anti-PD-1 compounds targeting MSI-H/dMMR tumors
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (SUPPL 5) : 102 - 106
  • [39] PD-1 blockade combined with COX inhibitor in patients with MSI-H/dMMR or high TMB, advanced or metastatic colorectal cancer (PCOX study)
    Wu, Zehua
    Hu, Huabin
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Ling, Jiayu
    Li, Weiwei
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] Clinical and molecular features of responders to PD-1 blockade for patients with MSI-H or dMMR advanced GI tumors
    Chida, Keigo
    Kawazoe, Akihito
    Kawazu, Masahito
    Nakamura, Yoshiaki
    Suzuki, Toshihiro
    Kuwata, Takeshi
    Shitara, Kohei
    Nakatsura, Tetsuya
    Yoshino, Takayuki
    CANCER SCIENCE, 2021, 112 : 399 - 399
12345